Department of Dermatology, Peking University First Hospital, Beijing, China.
National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
J Dermatol. 2023 Dec;50(12):1625-1628. doi: 10.1111/1346-8138.16936. Epub 2023 Aug 29.
Interleukin 17A (IL-17A) inhibitors, such as secukinumab, have been widely used as the mainstream treatment for chronic plaque psoriasis; however, cutaneous adverse events have been reported. Here, we report a 43-year-old Chinese man who developed herpetiform pemphigus (HP) during secukinumab treatment for his psoriasis. He presented with (1) clinical features of HP, which resembled bullous pemphigoid; histopathological features of intraepidermal blisters, eosinophilic/neutrophilic spongiosis, and liquefactive degeneration of the basal cell layer; (3) positive anti-desmoglein 1 antibody by enzyme-linked immunosorbent assay and cell surface IgG reactivity within the epidermis by indirect immunofluorescence assay; and (4) a satisfactory response to salicylazosulfapyridine (sulfasalazine). To the best of our knowledge, this is the first report of the development of HP after the use of secukinumab for psoriasis.
白细胞介素 17A（IL-17A）抑制剂，如司库奇尤单抗，已被广泛用于治疗慢性斑块型银屑病；然而，已经报道了皮肤不良反应。在此，我们报告了一例 43 岁的中国男性在使用司库奇尤单抗治疗银屑病期间发生疱疹样天疱疮（HP）。他表现为（1）HP 的临床特征，类似于大疱性类天疱疮；组织病理学特征为表皮内水疱、嗜酸性/中性粒细胞海绵形成和基底层液化变性；（3）酶联免疫吸附试验抗桥粒芯糖蛋白 1 抗体阳性和间接免疫荧光试验表皮内细胞表面 IgG 反应性；以及（4）柳氮磺胺吡啶（磺胺嘧啶）治疗反应良好。据我们所知，这是首例使用司库奇尤单抗治疗银屑病后发生 HP 的报告。
